Abstract:BackgroundGastric cancer (GC) remains a common disease with a poor prognosis worldwide. The SET binding protein 1 (SETBP1) has been implicated in the pathogenesis of several cancers and plays a dual role as an oncogene and a tumor suppressor gene. However, the role and underlying mechanism of SETBP1 in GC remain unclear.Materials and MethodsWe used next-generation RNA sequencing (RNA-seq) data from The Cancer Genome Atlas (TCGA) to explore the correlation between SETBP1 expression and tumor progression. We then quantified SETBP1 expression in GC cells with real-time quantitative polymerase chain reactions (RT-qPCR). The chi-square test and logistic regression were used to assess the correlation between SETBP1 expression and clinicopathological features. Kaplan-Meier survival analysis and Cox proportional hazards regression model were used to assess the relationship between SETBP1 expression and survival. Finally, gene set enrichment analyses (GSEA) were used to examine GC-related signaling pathways in low and high SETBP1 expressing samples.ResultsWe found SETBP1 expression levels in GC tissues to be significantly lower than in adjacent non-tumor tissues in the TCGA database. In addition, SETBP1 expression differed significantly between groups classified by tumor differentiation. Furthermore, SETBP1 expression in diffuse-type GC was significantly higher than in intestinal-type GC. However, it did not differ significantly across pathological- or T-stage groups. RT-qPCR and comprehensive meta-analysis showed that SETBP1 expression is downregulated in GC cells and tissues. Interestingly, SETBP1 expression in poorly- or un-differentiated GC cells was higher than in well-differentiated GC cells. Moreover, the chi-square test and logistic regression analyses showed that SETBP1 expression correlates significantly with tumor differentiation. Kaplan–Meier curves indicated that patients with relatively high SETBP1 expression had a poor prognosis. Multivariate analyses indicated that SETBP1 expression might be an important predictor of poor overall survival in GC patients. GSEA indicated that 20 signaling pathways were significantly enriched in samples with high and low SETBP1 expression.ConclusionSETBP1 may play a dual role in GC progression.

The impact of SETBP1 mutations in neurological diseases and cancer

New Insights into the Clinical Characteristics of SETD2-mutated Acute Myeloid Leukaemia.

Cyclin-dependent Kinase 1-Mediated Phosphorylation of SET at Serine 7 is Essential for Its Oncogenic Activity

Cell-type-specific gene expression and regulation in the cerebral cortex and kidney of atypical Setbp1S858R Schinzel Giedion Syndrome mice

[Expression Level of SET Gene in Acute Myeloid Leukemia and Its Clinical Significance].

Impact of TET2, SRSF2, ASXL1 and SETBP1 Mutations on Survival of Patients with Chronic Myelomonocytic Leukemia.

A functional single nucleotide polymorphism of SET8 is prognostic for breast cancer.

Clinical outcomes of patients diagnosed with SETBP1 mutated myeloid neoplasms

Novel SETBP1 D874V adjacent to the degron causes canonical schinzel–giedion syndrome: a case report and review of the literature

An Mir-502-Binding Site Single-Nucleotide Polymorphism In The 3 '-Untranslated Region Of The Set8 Gene Is Associated With Early Age Of Breast Cancer Onset

Identifying SETBP1 haploinsufficiency molecular pathways to improve patient diagnosis using induced pluripotent stem cells and neural disease modelling

Detection of a novel SETBP1 variant in a Chinese neonate with Schinzel–Giedion syndrome

The landscape of SETBP1 gene expression and transcription factor activity across human tissues

SETBP1 sets the stage

Mental retardation, seizures and language delay caused by new SETD1B mutations: Three case reports

Phenotypes of autism spectrum disorder and schizoaffective disorder associated with SETD1B gene but without intellectual disability and seizures

Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer

SE translation mRNA overexpression: a potential prognostic predictor in breast cancer

The Role of SETBP1 in Gastric Cancer: Friend or Foe

SETBP1 Haploinsufficiency and Related Disorders Clinical and Neurobehavioral Phenotype Study